P07: Universitätsklinikum Essen (UKES), Germany


The Clinic for Psychiatry and Psychotherapy belongs to the LVR-clinic Essen and is part of the University of Duisburg-Essen. The clinic provides 153 beds for patients with all psychiatric disorders. Special focus lies on the treatment and the research of neurodegenerative disorders. Therefore the centre for geronto-psychiatry consisting of a closed ward, a day hospital and the Laboratory for molecular Neurobiology was established within the hospital.

Currently the personnel of the clinic for psychiatry and psychotherapy comprise around 50 physicians and scientists as well as more than 100 other health professionals. 

The consortium will especially profit from the international acknowledged expertise in the field of neurodegenerative diseases, the specialised wards for geronto-psychiatry where patients will be diagnosed according to state of the art criteria. In the centre for geronto-psychiatry approximately 80 patients suffering from dementia are diagnosed and treated each year.

The laboratory for Molecular Neurobiology was started in October 2008 and encompasses approximately 300m2 of laboratory space. The instrumentation includes amongst others 2 fully equipped cell culture labs, a MSD electrochemiluminescence Reader, an ELISA reader, 1- and 2-D Electrophoresis equipment with a highly sensitive INTas imager for chemiluminescence quantification and an Agilent off gel fractionator.   


  • UKES/UMG fulfilled the role of the work package leader for WP7 (pre-clinical and clinical testing).
  • Together with the other clinical partners (UULM and UEF), UKES contributed to the collection of human blood plasma and cerebrospinal fluid samples from relevant and well characterized patient- and disease control groups.
  • A list of proposed validation parameters to be assessed for initial, partial validation of novel technologies was provided to the NADINE consortium by UKES/UMG.
  • As a “gold standard” reference method for evaluating novel technologies, UKES/UMG selected a commercially available electrochemiluminescence immunoassay for the simultaneous measurement of the Aβ-peptides Aβ38, Aβ40 and Aβ42. The assay was subjected to a comprehensive series of assay validation tests and passed defined acceptance criteria regarding intra- and inter-assay reproducibility, selectivity and parallelism. Finally the assay was applied to measuring the three different Aβ variants in approximately 200 CSF samples from the UKES- collection.
  • Together with partners ICRM, DS, DTU and KTH, a comprehensive report on comparison and evaluation of analysis methods was provided to the consortium by UKES/UMG.



27 OCTOBER 2020